Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.60 |
| ▸ | BACE1 | P56817 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.50 |
| ▸ | PDE10A | Q9Y233 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | NPFFR1 | Q9GZQ6 | 1/20 | 0.47 |
| ▸ | NPFFR2 | Q9Y5X5 | 1/20 | 0.47 |
| ▸ | ACHE | P22303 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13777688 | 0.85 | KDM4E (0.62) | CYP1A2BACE1KDM4EPDE10AALDH1A1 | |
| SCHEMBL4848307 | 0.83 | CYP1A2 (0.58) | CYP1A2BACE1KDM4EPDE10AALDH1A1 | |
| SCHEMBL3396050 | 0.83 | CYP1A2 (0.58) | CYP1A2BACE1KDM4EPDE10AALDH1A1 | |
| SCHEMBL28589683 | 0.83 | CYP1A2 (0.58) | CYP1A2BACE1KDM4EPDE10AALDH1A1 | |
| SCHEMBL526457 | 0.83 | CYP1A2 (0.58) | CYP1A2BACE1KDM4EPDE10AALDH1A1 | |
| SCHEMBL9184895 | 0.82 | KDM4E (0.50) | CYP1A2BACE1KDM4EALDH1A1HPGD | |
| SCHEMBL8671753 | 0.82 | CYP1A2 (0.53) | CYP1A2BACE1KDM4EPDE10AALDH1A1 | |
| SCHEMBL25523587 | 0.81 | CYP1A2 (0.51) | CYP1A2BACE1KDM4EPDE10AALDH1A1 | |
| SCHEMBL3970182 | 0.81 | KDM4E (0.49) | CYP1A2KDM4EALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL10733967 | 0.80 | ADAM17 (0.46) | CYP1A2KDM4EALDH1A1HPGDSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117945995-A | Alkylated nitrogen-containing heterocyclic compound and preparation method and application thereof | 中国科学院青海盐湖研究所 | 2024-04-30 | — | — | CN | disclosed |
| US-11302870-B2 | Materials for electronic devices | MERCK PATENT GMBH (DE) | 2022-04-12 | — | — | US | disclosed |
| US-20190288206-A1 | MATERIALS FOR ELECTRONIC DEVICES | MERCK PATENT GMBH (DE) | 2019-09-19 | — | — | US | disclosed |
| CN-106833623-B | A kind of fluorescence probe and preparation method thereof | 广东工业大学 | 2019-08-06 | — | — | CN | disclosed |
| WO-2018067659-A1 | A CHEMOPROTEOMIC APPROACH FOR DISCOVERING COVALENT LIGANDS FOR DIVERSE PROTEIN TARGETS | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2018-04-12 | — | — | WO | disclosed |
| CN-106833623-A | A kind of fluorescence probe and preparation method thereof | 广东工业大学 | 2017-06-13 | — | — | CN | disclosed |
| US-20120196845-A1 | QUINOLINONE-PYRAZOLONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK SHARP & DOHME LLC | 2012-08-02 | — | — | US | disclosed |
| US-7595317-B2 | Barbituric acid derivatives as inhibitors of TNF-α converting enzyme (TACE) and/or matrix metalloproteinases | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-09-29 | — | — | US | disclosed |
| US-7294624-B2 | Osteoporosis; antiarthritic agents | BRISTOL MYERS SQUIBB COMPANY (US) | 2007-11-13 | — | — | US | disclosed |
| US-20070167451-A1 | BARBITURIC ACID DERIVATIVES AS INHIBITORS OF TNF-alpha CONVERTING ENZYME (TACE) AND/OR MATRIX METALLOPROTEINASES | DUAN JINGWU | 2007-07-19 | — | — | US | disclosed |
| US-7015217-B2 | Cyclic sulfone derivatives as inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme (TACE) | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-03-21 | — | — | US | disclosed |
| US-6962938-B2 | Spiro-cyclic β-amino acid derivatives as inhibitors of matrix metalloproteases and TNF-α converting enzyme (TACE) | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2005-11-08 | — | — | US | disclosed |
| US-6720329-B2 | ANTIINFLAMMATORY AGENTS | BRISTOL-MYERS SQUIBB PHARMA | 2004-04-13 | — | — | US | disclosed |
| WO-2003053941-A2 | BARBITURIC ACID DERIVATIVES AS INHIBITORS OF TNF-ALPHA CONVERTING ENZYME (TACE) AND/OR MATRIX METALLOPROTEINASES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-07-03 | — | — | WO | disclosed |
| WO-2003040103-A1 | β-SULFONE DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES AND/OR TNF-α CONVERTING ENZYME (TACE) | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-05-15 | — | — | WO | disclosed |
| WO-2003031431-A1 | CYCLIC SULFONE DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES AND/OR TNF-$G(A) CONVERTING ENZYME (TACE) | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-04-17 | — | — | WO | disclosed |
| US-4684693-A | Thermosettable polymer or prepolymer prepared from heterocyclic materials containing a nitrogen atom and carboxylic acid mono- or dianhydride with N,N'-bis-imide | THE DOW CHEMICAL COMPANY (US) | 1987-08-04 | — | — | US | disclosed |
| EP-0107988-B1 | IMIDAZO (1,2-A)QUINOLINES, THEIR SALTS, THEIR PREPARATION, THEIR USE AS MEDICAMENTS AND COMPOSITIONS CONTAINING THEM | ROUSSEL-UCLAF (FR) | 1987-07-29 | — | — | EP | disclosed |
| US-4668767-A | Thermosettable polymer or prepolymer prepared from heterocyclic material containing a nitrogen atom and carboxylic acid mono- or dianhydride | THE DOW CHEMICAL COMPANY (US) | 1987-05-26 | — | — | US | disclosed |
| US-4647616-A | Thermosettable polymer or prepolymer prepared from herterocycle material containing a nitrogen atom and carboxylic acid mono- or dianhydride | THE DOW CHEMICAL COMPANY (US) | 1987-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11302870-B2 | Materials for electronic devices | EFNA1, PNMT, FLNB | CYP1A2 139/4885BACE1 3326/4885KDM4E 2604/4885 |
| US-20070167451-A1 | BARBITURIC ACID DERIVATIVES AS INHIBITORS OF TNF-alpha CONVERTING ENZYME (TACE) AND/OR MATRIX METALLOPROTEINASES | TNF, MMP9, MMP3 | CYP1A2 1247/4885BACE1 72/4885KDM4E 2397/4885 |
| US-20190288206-A1 | MATERIALS FOR ELECTRONIC DEVICES | EFNA1, PNMT, FLNB | CYP1A2 135/4885BACE1 3291/4885KDM4E 2613/4885 |
| US-20120196845-A1 | QUINOLINONE-PYRAZOLONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | CHRM1, OPRL1, CHRNA5 | CYP1A2 356/4885BACE1 111/4885KDM4E 1962/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.